burgdorferi sensu stricto, B. garinii, and B. afzelii (1) (2) (3) . Months after the disease's onset, about 60% of untreated North American patients develop arthritis. The synovial lesion in patients with chronic Lyme arthritis is similar to that found in other forms of chronic inflammatory arthritis, including rheumatoid arthritis. There is a lymphoplasmacellular infiltrate, intense HLA-DR and -DQ expression throughout, and the majority of T cells are CD4 positive (4) . While most patients with Lyme arthritis are cured with antibiotic therapy, about 10% have persistent arthritis for months or even several years after antibiotic treatment (2, 5) . Patients may thus be divided into two groups: those with treatmentresponsive arthritis, defined as arthritis resolving after the appropriate antibiotic treatment, and those with treatment-resistant arthritis, which persists after treatment (5 In the light of our findings (18) , the most tempting hypothesis would be the existence of an arthritogenic epitope on OspA. Crossreactivity of the OspA epitope with a self epitope would then lead to autoreactivity via molecular mimicry (27) . A recent search of the Gen-Bank, EMBL, and Swissprot databases did not reveal significant sequence homologies between OspA and any human proteins. Obviously, those databases include only a minority of possible selfantigens. Furthermore, a recent study has shown that simple sequence alignment may not identify molecular mimicry (28) . T cell clones from multiple sclerosis patients, specific for an immunodominant epitope of myelin basic protein (MBP), were used to identify the structural requirements for MHC binding and TCR recognition of the peptide; databases were then searched for potentially cross-reactive peptides. Of the seven bacterial and viral peptides which activated the MBPspecific T cell clones, only one was identified by sequence alignment. This study suggests that molecular mimicry could be identified in Lyme arthritis by using OspA-specific T cell clones from patients with treatment-resistant Lyme arthritis to determine the structural requirements for the binding of an immunodominant OspA epitope to HLA and for the recognition of the peptide-HLA complex by the TCR.
If molecular mimicry between OspA and a self-epitope exists, one would have to ask why the patients' T cells are not tolerant of the crossreactive arthritogenic epitope on OspA. As described above, unlike OspA, OspB is frequently recognized by TCLs from patients with either form of Lyme arthritis (18) . We therefore hypothesize that a mechanism of "epitope spreading", in which the T cell progressively recognizes more epitopes on a protein antigen during an immune response (29) , occurs in some patients. The scenario suggests that OspB is an immunodominant antigen for patients with Lyme borreliosis. In most patients, the T cell response to OspB remains focused on OspB epitopes that are not highly homologous to OspA. In a minority of patients, however, chronic antigenic stimulation results in the spreading of T cell recognition from OspB epitopes that are not homologous to OspA to OspB epitopes which are similar to OspA epitopes. Indeed, two T cell clones which recognize a peptide epitope contained on both OspA and OspB have been identified (30 
OTHER MECHANISMS FOR IMMUNOPATHOLOGY
All of this could reasonably be regarded as prolegomena to any future hunt for the infectious trigger of rheumatoid arthritis. However, even if, as we hypothesize, T cell recognition of an arthritogenic epitope on OspA plays a role in the pathogenesis of treatment-resistant Lyme arthritis, other factors must be involved (18) . Cytokine production is an obvious possibility. Upon stimulation with B. burgdorferi, T cell production of interferon-y occurs in arthritis-susceptible mice, while IL-4 is produced in arthritis-resistant mice (31) . Clearly, T cell cytokines are not the only compounds involved; the balance of IL-,B and IL-i 3 receptor antagonist is disturbed in the synovial fluid of patients with treatment-resistant Lyme arthritis but not in patients with treatment responsive Lyme arthritis (32 (35) . However, both the vaccine-induced T cell-mediated immunopathology in hamsters (19) and our own data on T cell recognition of OspA (18) raise the spectre of immunopathology. Since Lyme borreliosis is cured with antibiotic therapy in most patients, the benefits and potential risks of immunizing people with OspA should be weighed carefully, pending a better understanding of the protective and disease-enhancing aspects of the immune response.
